155 results
8-K
EX-99.2
NVTAQ
Invitae Corp
12 Jan 21
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
6:06am
Exhibit 99.2
INVITAE From genetics, health J.P. Morgan Healthcare Conference 01 | 12 | 21
Safe harbor statement This presentation contains forward …
Invitae’s mission is to bring comprehensive genet mainstream medicine t improve healthcare for billions of people © 2021 Invitae Corporation. All
8-K
EX-99.1
NVTAQ
Invitae Corp
11 Jan 22
Invitae Reports Preliminary 2021 Revenue of More Than $458 Million and Billable Volume of More Than 1.16 Million
4:20pm
year-over-year in revenues
76 percent growth year-over-year in billable volumes
Ended the year with more than 17,500 active healthcare provider … for data sharing
— Presenting at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 9:45 a.m. Eastern/6:45 a.m. Pacific —
SAN
8-K
EX-99.1
NVTAQ
Invitae Corp
7 Jan 19
Results of Operations and Financial Condition
8:04am
by strong commercial execution, test menu expansion and the accelerating use of genetics in healthcare.
“We envisioned a world in which genetic … information can inform healthcare decisions throughout every stage of life, and that is rapidly becoming a reality. Invitae’s strong 2018 results
8-K
EX-99.1
NVTAQ
Invitae Corp
12 Jun 18
Regulation FD Disclosure
7:31am
information into mainstream medical practice to improve the quality of healthcare for billions of people Genetic information is more valuable when … shared Driving down the cost of genetic information will increase its personal and clinical utility Healthcare professionals are fundamental in ordering
8-K
EX-99.1
NVTAQ
Invitae Corp
12 Jan 21
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
6:06am
— Presenting at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021 at 10:50 a.m. Eastern/7:50 a.m. Pacific —
SAN FRANCISCO, January 11 … in light of the impact of the COVID-19 pandemic on the healthcare system throughout the year,” said Sean George, Ph.D., co-founder and chief
8-K
EX-99.1
pngr4bulj0cj
7 Sep 21
Invitae to Acquire Ciitizen to Strengthen its Patient-Consented Health Data Platform to Improve Personal Outcomes and Global Research
8:01am
8-K
EX-99.3
3zzvajiz540
18 Jul 22
Invitae Announces Strategic Business Realignment to Accelerate Its Path to Positive Cash Flow
9:28pm
8-K
EX-99.2
v1eq e062mkvndw4x
7 Sep 21
Invitae to Acquire Ciitizen to Strengthen its Patient-Consented Health Data Platform to Improve Personal Outcomes and Global Research
8:01am
8-K
EX-99.1
u0h8xh mzg
18 Jul 22
Invitae Announces Strategic Business Realignment to Accelerate Its Path to Positive Cash Flow
9:28pm
8-K
EX-99.1
y90hilzzpu13h88
10 Mar 20
Invitae to Acquire YouScript and Genelex to Make it Easier to Use Pharmacogenetic Information at the Point of Care
4:33pm
8-K
EX-99.3
yf9ly r02w12m0egjo44
22 Jun 20
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
4:55pm
425
cl05n ymux7074xzoim
22 Jun 20
Business combination disclosure
5:30pm
8-K
EX-99.1
zartmvypr
5 Apr 21
Invitae Announces $1.15 Billion Investment Supporting Ongoing Growth Initiatives
4:13pm
10-K
pzu5581u rboefg2id
30 Mar 15
Annual report
12:00am
8-K
EX-99.1
tv80m2pkv
22 Jun 20
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
4:55pm
8-K
EX-99.1
kaay7
13 Nov 19
Invitae to Acquire Clear Genetics
4:09pm
8-K
EX-99.1
6iu3j396vbvcz1 ge1uv
13 Jan 20
Results of Operations and Financial Condition
5:11pm
8-K
EX-99.2
r9m65pt g0
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm